Child Immunization Schedule Addendum (Updated June 27, 2024)

Recommendations for Ages 18 Years or Younger, United States, 2024

Purpose

Outline new or updated vaccine recommendations that have occurred since October 26, 2023.

How to use the schedule

Vaccines in the Child Immunization Schedule

To make vaccination recommendations, healthcare providers should:

  1. Determine recommended vaccine by age (Table 1 – By Age)
  2. Determine recommended interval for catch-up vaccination (Table 2 – Catch-up)
  3. Assess need for additional recommended vaccines by medical condition or other indication (Table 3 – By Medical Indication)
  4. Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)
  5. Review contraindications and precautions for vaccine types (Appendix)
  6. Review new or updated ACIP guidance (Addendum)

Addendum

In addition to the recommendations presented in the previous sections of this immunization schedule, ACIP has approved the following recommendations by majority vote since October 26, 2023. The following recommendations have been adopted by the CDC Director and are now official. Links are provided if these recommendations have been published in Morbidity and Mortality Weekly Report (MMWR).

Vaccines Recommendations Effective Date of Recommendation*
COVID-19 (Moderna,
Pfizer-BioNTech, Novavax)		 ACIP recommends 2024-2025 COVID-19 vaccines as authorized or approved by FDA in persons ≥6 months of age. June 27, 2024
Influenza
  • ACIP reaffirms the recommendation for routine annual influenza vaccination of all persons aged ≥6 months who do not have contraindications.
  • ACIP recommends high-dose inactivated (HD-IIV3) and adjuvanted inactivated (aIIV3) influenza vaccines as acceptable options for influenza vaccination of solid organ transplant recipients aged 18 through 64 years who are on immunosuppressive medication regimens, without a preference over other age-appropriate IIV3s or RIV3.
 June 27, 2024
Vaxelis (DTaP-IPV-Hib-HepB) ACIP recommends DTaP-IPV-Hib-HepB (Vaxelis®) should be included with PRP-OMP (PedvaxHIB®) in the preferential recommendation for American Indian and Alaska Native infants based on the Haemophilus influenzae type b (Hib) component. June 26, 2024

*The effective date is the date when the CDC director adopted the recommendation and when the ACIP recommendation became official.

Print
Content Source:
National Center for Immunization and Respiratory Diseases